



GUIDELINES FOR MEMBERSHIP IN THE UNIVERSITY OF COLORADO CANCER CENTER

The University of Colorado Cancer Center (the “Center”) has been designated a *consortium comprehensive cancer center* by the National Cancer Institute of the National Institutes of Health. The Center receives support from the National Cancer Institute under Cancer Center Support Grant (CCSG) P30CA046934. The cancer center consortium has 6 members: University of Colorado Denver, University of Colorado Boulder, Colorado State University, University of Colorado Hospital, Children’s Hospital Colorado and the Denver VA Medical Center. *Our ability to maintain this designation and grant is dependent upon having as center members investigators that focus on cancer research.*

Section 1. Eligibility

Center membership is available to faculty that focus on cancer in basic, clinical, translational, or population-based research irrespective of their affiliation with consortium institutions. Application for membership is voluntary and indicates agreement by the applicant with the Center’s *Expectations of Membership* defined below. Applications are taken from individuals, not groups or institutions.

Section 2. Application Process

Candidates must submit an online application. <https://smr.to/p67828> (Questions: jill.penafiel@cuanschutz.edu). A complete application consists of **1)** a completed Membership Application Form; **2)** the Cancer Relevance Information Statement; and **3)** a current copy of the applicant’s NIH biosketch in the current NIH format. Applications will be reviewed by the Program Leaders who will recommend membership status and program assignment to the Center’s Governance Committee. Decisions on membership are made by the CU Cancer Center Governance Committee, with additional discretion exercised by the CU Cancer Center Director under exceptional circumstances.

Section 3. Membership Categories

Four types of Membership are granted:

3.1. Full Member: Full membership will be considered if the applicant has a research focus in either basic, clinical, translational, or population-based cancer research. Full Member status will be considered if the applicant meets criteria 1 and 2, or 3:

1a. Is currently the Principal Investigator (PI) of an independent cancer-focused research program (lab, clinical or population science) and 1b. PI of an active R01-equivalent peer-reviewed cancer research grant as defined by the NCI¹, **or** is national PI of a cancer clinical

¹ A list of NCI-defined peer-reviewed sponsors are located at <http://cancercenters.cancer.gov/PoliciesResources/PoliciesResources#>. Other funding sponsors are considered non-peer reviewed by the NCI’s criteria.

trial; and

2. Is an author on at least three peer-reviewed papers published within the past three years that are significantly cancer-related (in-press publications are considered); or
3. Holds a *significant* leadership role in the CU Cancer Center.

3.2. Affiliate Member: Affiliate membership will be considered if the applicant contributes to either basic, translational, or population-based cancer research or cancer education. Affiliate Member status will be considered if the applicant meets criteria 1 or 2 or 3:

1. Is the PI of non-peer reviewed¹ cancer-focused sponsored research within the past three years; or
2. Is an author on at least two peer-reviewed papers with significant cancer focus published within the past five years (in-press publications are considered); or
3. Has emerging interest in cancer and conducting research with a Cancer Center Member.

3.3. Clinical Member: Clinical membership will be considered if the applicant meets criteria 1 or 2*:

1. contributes to clinical cancer research by serving as the local PI of a cancer-related clinical trial within the past three years; or
2. Is a significant contributor to Cancer Clinical Trials within the last 5 years that accrue patients to CU Cancer Center trials including but not limited to: CU, UCH, CHCO and the VA.

*Applicants that qualify for affiliate or clinical member status may be considered for Full member status under the following circumstances:

1. *Cancer Center Leaders:* At the Director's discretion, individuals who hold CCSG leadership roles but who do not otherwise qualify for Full member status may be granted Full member status.
2. *Clinical Investigators:* Investigators who contribute significantly to the Center's research mission with a robust portfolio of actively accruing clinical trials may be nominated by Program Leaders for Full member status.

3.4. Mentored Member. Mentored membership will be considered if the applicant has a research focus in either basic, clinical, translational or population-based cancer research and meets criteria 1 through 4:

1. Is within the first 5 years of their first faculty appointment at the level of Assistant Professor (or equivalent); and
2. Has established, or is on the verge of establishing, an *independent* program in cancer research (lab, clinical, or population science based); and
3. PI of peer or non-peer reviewed cancer-focused sponsored research within the past 3 years; and
4. Author on at least 2 peer-reviewed papers with significant cancer focus published within the last 5 years.

Candidates must be nominated for Mentored Member status by the Program Leaders. Nomination occurs during review of the application, at which time applicants in this category are required to develop a formal mentoring plan that must be approved by the CU Cancer Center Governance Committee. Mentored Member status confers the same privileges of Full member status, but for a limited time as outlined below. Nominations are subject to approval by the Governance Committee. If Mentored Member status is granted, the initial membership will be for 5 years, renewable for 5 additional years at the discretion of the Program Leaders and with Governance Committee approval. Additional time at the Mentored Member level may be granted at the discretion of the Director. The expectation is that most Mentored Members will meet the criteria to be a Full member within 5 years.

Section 4. Ongoing Membership Review

All members are reviewed annually by Program Leaders in conjunction with the preparation of the CCSG progress report to determine ongoing adherence with the criteria specified for the membership categories above. Full members who no longer meet the criteria but remain clear contributors to on-going cancer research, may be retained as Full members at the request of the Program Leaders and with concurrence from the Governance Committee and approval by the Director. When making these exceptions, the Governance Committee and Director will take into consideration the overall strength of the Program's peer-reviewed grant portfolio to insure the Program retains a critical mass of peer-reviewed funding to achieve significant scientific impact. To facilitate this annual review, members may be asked to provide information regarding their publications and sponsored research awards, as well as an updated statement of their cancer research. Non-response to requests will jeopardize continuation of membership.

Section 5. Appeals

Individuals may appeal decisions regarding eligibility or changes to their membership status or category. Appeals should be submitted to the Administrative Office (Michaela.Montour@cuanschultz.edu) and should include evidence of compliance with membership criteria. The appeal will be considered by the Governance Committee and if approved by the Governance Committee, will be forwarded to the Director for final approval.

Section 6. Benefits of Membership

6.1 Affiliate and Clinical Members are eligible for:

1. Participation in Center-wide or program-based research symposia and retreats; attendance at special presentations; participation in community engagement, education and training activities.
2. Intramural funding opportunities provided by the Center, with the exception of pilot projects supported by CCSG Developmental Funds.
3. Announcement of new research developments and clinical breakthroughs by Center media relations professionals.
4. Support from the Cancer Center's Oncology Clinical Research Support Team (OCRST) for development of approved investigator-initiated trials.
5. Access to the Cancer Clinical Trials Office shared resource for trial support.

6.2 Full and Mentored Members are eligible for all Affiliate/Clinical Membership benefits outlined above and the following:

1. Consideration for nomination by the Center to national cancer-specific funding opportunities that limit the number of applications per institution (e.g. the Damon Runyon Cancer Research Foundation; Samuel Waxman Foundation; Mary Kay Foundation; and the V Foundation);
2. Access to the Center's Administrative Office for support of:
 - a. Development and submission of large, multi-departmental cancer-specific grants;
 - b. Planning, scheduling and organization of Center endorsed activities benefiting a large contingent of the membership;
3. Access to the Center's basic and data science shared resources at subsidized rates for support of their cancer-related research activities; and
4. Support from CCSG Developmental Funds designated for intramural pilot projects.

Section 7. Expectations of Membership

The Cancer Center is an NCI-designated comprehensive cancer center. To maintain this designation, we expect each member to:

1. Participate in the Center sponsored symposia, retreats, seminars, and surveys.
2. Provide annual lay and scientific progress reports for pilot projects and other funding from the Center.
3. Provide information regarding publications, grant submissions and awards, and any other research resources developed as a result of the funding provided by the Cancer Center.
4. Submit all human subject research protocols to the Protocol Review and Monitoring Committee in advance of IRB submission, and abide by the Cancer Center's NCI-approved Data & Safety Monitoring Plan.
5. Acknowledge the CCSG and use of Center Shared Resources in publications as below and submit publications to PubMed Central. Our NCI designation is tied to our Cancer Center Support Grant; and our grant subject to NIH's Public Access Policies. Repeated failure to submit publications to PubMed Central may result in suspension of privileges to use Cancer Center shared resources.

"This work was supported in part by the University of Colorado Cancer Center's _____ Shared Resource funded by NCI grant P30CA046934."

OR

"Supported in part by the _____ Shared Resource of the Colorado Cancer Center Support Grant P30CA046934."

UNIVERSITY OF COLORADO CANCER CENTER

SENIOR LEADERSHIP

Director and Associate Directors	Senior Leader	Email Address	Campus Box Address	Phone
Director	R. Schulick, MD, MBA, FACS	Richard.Schulick@cuanschutz.edu	F434	303-724-3152
Deputy Directors	C. Bradley, PhD	Cathy.Bradley@cuanschutz.edu	F434	303-724-9526
	J. DeGregori, PhD	James.DeGregori@cuanschutz.edu	8101	303-724-3230
Associate Directors				
Basic Research	H. Ford, PhD	Heide.Ford@cuanschutz.edu	6115	303-724-3509
Clinical Research	C. Lieu, MD	Christopher.Lieu@cuanschutz.edu	8117	303-724-6390
Population Sciences Research	C. Bradley, PhD	Cathy.Bradley@cuanschutz.edu	F434	303-724-9526
Translational Research	W. Messersmith, MD	Wells.Messersmith@cuanschutz.edu	8117	303-724-0747
Community Outreach & Engagement	E. Borrayo, PhD	Evelinn.Borrayo@cuanschutz.edu	F434	303-724-3152
Clinical Services	T. Purcell, MBA MD	Tom.Purcell@cuanschutz.edu	8117	720-848-8093
Cancer Research Training & Education Coordination	E. Davila, PhD	Eduardo.Davila@cuanschutz.edu	8117	303-724-0817
Administration & Finance	S. Farmer, MHA	Stephanie.Farmer@cuanschutz.edu	F434	303-724-5724

RESEARCH PROGRAMS

Detailed descriptions of the programs are available on the Cancer Center's website under Research: www.coloradocancercenter.org.

Program	Program Leaders	Email Address	Campus Box/ Address	Phone
Basic Sciences				
Molecular & Cellular Oncology	C. Jordan, PhD	Craig.Jordan@cuanschutz.edu	B170	303-724-8804
	TT. Su, PhD	Tin.Su@colorado.edu	CU Boulder 347	303-724-8165
Translational Sciences				
Tumor-Host Interactions	J. Richer, PhD	Jennifer.Richer@cuanschutz.edu	8104	303-724-3735
	M. Verneris, MD	Michael.Verneris@cuanschutz.edu	A036/B115	720-777-1234
	J. Slansky, PhD	Jill.Slansky@cuanschutz.edu	8333	303-724-8665
Developmental Therapeutics	L. Gore, MD	Lia.Gore@cuanschutz.edu	A036/B115	720-777-6772
	D. Gustafson, PhD	Daniel.Gustafson@colostate.edu	CSU	970-297-1278
	A. Jimeno, MD PhD	Antonio.Jimeno@cuanschutz.edu	8117	303-724-2478
Population Sciences				
Cancer Prevention and Control	J. Studts, PhD	Jamie.Studts@cuanschutz.edu	F434	303-724-8421
	R. Agarwal, PhD	Rajesh.Agarwal@cuanschutz.edu	C238-P15	303-724-4055

SHARED RESOURCES

Shared Resource	Director	Manager	Contact Email Address	Location
Administration	S. Farmer, MHA	M. Montour, MPA J. Quinn, MBA, MHA M. Ward, BS, MACC	Michaela.Montour@cuanschutz.edu Jason.Quinn@cuanschutz.edu Marshall.Ward@cuanschutz.edu	AMC
Animal Imaging <i>MRI/CT/PET & MRS;</i> <i>Optical Imaging</i>	N. Serkova, PhD	J. Steiner	Jenna.Steiner@cuanschutz.edu	AMC
Biostatistics / Bioinformatics <i>Biostatistics</i> <i>Bioinformatics</i>	D. Gao, PhD J. Costello, PhD	A. Nicklawsky, PhD A. Goodspeed, PhD	Andrew.Nicklawsky@cuanschutz.edu Andrew.Goodspeed@cuanschutz.edu	AMC AMC
Cell Technologies	S. Anderson, PhD	L. Sherman, BS	Lori.Sherman@cuanschutz.edu	AMC
Flow Cytometry	E. Clambey, PhD	A. Acosta, MBA	Alistaire.Acosta@cuanschutz.edu	AMC
Functional Genomics	J. Espinosa, PhD	M. Joshi	Molishree.Joshi@cuanschutz.edu	AMC
Genomics	B. Gao, PhD	K. Diener	Katrina.Diener@cuanschutz.edu	AMC
Image-Guided Precision Irradiator	S. Karam, MD PhD	B. Van Court, BS BE	Benjamin.VanCourt@cuanschutz.edu	AMC
Metabolomics	A. D'Alessandro, PhD	J. Reisz Haines	Julie.Haines@cuanschutz.edu	AMC
Molecular Pathology <i>Cytogenetics</i> <i>Pre-analytic Evaluation</i> <i>& Molecular Testing</i>	L. Bao, PhD D. Aisner, MD PhD	H. Nijmeh, PhD K. Davies, PhD	Hala.Nijmeh@cuanschutz.edu Kurtis.Davies@cuanschutz.edu	AMC AMC
Pharmacology	D. Gustafson, PhD	D. Gustafson, PhD	Daniel.Gustafson@ColoState.edu	CSU
Population Health	J. Studts M. Perrailon	E. Meyer	Elisabeth.Meyer@cuanschutz.edu	AMC
Proteomics	K. Hansen, PhD	M. Dzieciatkowska	Monika.Dzieciatkowska@cuanschutz.edu	AMC
Structural Biology <i>X-ray Crystallography</i> <i>NMR Spectroscopy</i>	M. Churchill, PhD D. Jones, PhD	J. Hardin, PhD D. Jones, PhD	John.Hardin@cuanschutz.edu David.Jones@cuanschutz.edu	AMC AMC
Tissue Biobanking & Histology <i>Biobanking</i> <i>Laser Capture</i> <i>Microdissection</i> <i>Histology</i>	S. Lucia, MD A. vanBokhoven, PhD	A. Osypuk E. Smith	Andrea.Osypuk@cuanschutz.edu Elizabeth.E.Smith@cuanschutz.edu	AMC

Other Support Elements for Human Subject Research

Oncology Research Support Team	C. Lieu, MD	S. Grolnic	Stacy.Grolnic@cuanschutz.edu	AMC
Protocol Review & Monitoring	C. Cost, MD	D. McCollister	PRMC.UCHSC@ucdenver.edu	AMC
Data & Safety Monitoring	P. Kabos, MD	A. Wise	Andrew.Wise@cuanschutz.edu	AMC
Oncology-Focused Clinical Trial Offices				
Cancer Clinical Trials Office (CCTO)	A. Elias, MD (Interim)	T. Colvin	Tiffany.Colvin@cuanschutz.edu	AMC
Hematology Clinical Trials Unit (HCTU)	C. Smith, MD	D. Schatz	Derek.Schatz@cuanschutz.edu	AMC
CCBD Research Center	K. Maloney, MD	T. O'Lonegan	Theresa.O'Lonegan@childrenscolorado.org	CHCO
VA Clinical Trials Office	D. Bowles, MD	C. Hutchinson	Caitlin.Hutchinson2@VA.gov	VA
Clinical Trials Office @ Highlands Ranch	E. Lam	T. Colvin	Tiffany.Colvin@cuanschutz.edu	HRH